Clinical Trials for Liver Cancer

An Open-Label, Dose Escalation, Phase I/II Clinical Trial of ET140203 T Cells in Pediatric Subjects With Relapsed/Refractory Hepatoblastoma (HB), Hepatocellular Neoplasm-Not Otherwise Specified (HCN-NOS), or Hepatocellular Carcinoma (HCC)

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: Pediatric and young adult patients (1–21 years) with relapsed/refractory, AFP-high (≥100 ng/mL), HLA-A2–positive hepatoblastoma, HCN-NOS, or HCC receive a single infusion of autologous ET140203 T cells after lymphodepletion. ET140203 (JWATM-203) is an engineered T-cell therapy using an ARTEMIS receptor with a TCR-mimic that targets AFP158–166/HLA-A*02:01 to selectively kill AFP+/HLA-A2+ liver cancer cells.

ClinicalTrials.gov ID: NCT04634357